Biosimulation Technology Market Professional Survey Regional Analysis of the Market

The global biosimulation market is growing significantly due to technological advancements and increasing research and development investment in the pharmaceutical and biotechnology industries. Low success rate of drug approval and emerging software applications of biosimulation technology are creating ample opportunities for the biosimulation technology market to grow at a significant rate in the forecasted period.The advanced research and development facilities and new product developments by the companies are propelling the demand for cost effective biosimulation software.

Request for report sample at: https://www.psmarketresearch.com/market-analysis/biosimulation-technology-market/report-sample

Biosimulation technology market can be categorized on the basis of applications, end-users, and product types. Based on applications, the biosimulation technology market can be categorized as drug development, drug discovery, and others. Drug development segment includes preclinical testing and clinical trials; whereas, drug discovery segment includes target identification and validation, and lead identification and optimization. Drug development segment leads the biosimulation technology market. Based on end-users, biosimulation technology market can be categorized as pharmaceutical and biotechnology companies, academic institutes and research laboratories, contract research organizations, and others. Pharmaceutical and biotechnology companies lead the biosimulation technology market.

On the basis of product types, biosimulation market can be categorized as software and services. Software segment includes pharmacodynamic/pharmacokinetic modeling and simulation software, molecular modeling and simulation software, physiologically-based pharmacokinetic modeling and simulation software, toxicity prediction software, trial design software, and other software. Services segment includes contract services and in-house services. Software segment leads the biosimulation market.

Browse report at: https://www.psmarketresearch.com/market-analysis/biosimulation-technology-market

Some of the major players operating in the global biosimulation technology market Dassault Systemes SA, Simulation Plus Inc., Certara USA, Inc., Advanced Chemistry Development, Inc., In Silico Biosciences, Inc., Chemical Computing Group, Inc., Physiomics PLC., Rhenovia Pharma Ltd., Genedata AG, Entelos Holding Corporation, Leadscope, Inc., and Schrodinger Inc. among others.

Source: P&S Intelligence

Molecular Cytogenetics Market Competitive Landscape Analysis with Forecast by 2023

Global molecular cytogenetics market is forecasted to attain revenue of $3.3 billion by 2023. The market is mainly driven by growing implementation of pharmacogenomics in personalized disease management and drug development, rising cancer cases, advancements in cytogenetic techniques, and rise in genetic-based prediction of chromosomal abnormalities.

Download free report sample at: https://www.psmarketresearch.com/market-analysis/molecular-cytogenetics-market/report-sample

Based on offering, the molecular cytogenetics market has been categorized into consumables, software and services and instruments. Globally, the market for software and services is expected to register fastest growth, with CAGR of 10.5% during the forecast period. This can be attributed to rapid adoption of automation in laboratory process and rising preference for outsourcing of expensive services.

Based on technology, the molecular cytogenetics market has been categorized into comparative genomic hybridization (CGH), fluorescence in-situ hybridization (FISH), immunohistochemistry, karyotyping and others. The karyotyping technology market for molecular cytogenetics is further categorized into spectral and virtual. In 2017, spectral karyotyping held larger share, of 66.0%, in molecular cytogenetics market, owing to the usage of these technique for the detection of complex chromosomal aberration as well as for identification of new leukaemia subgroups.

Browse report at: https://www.psmarketresearch.com/market-analysis/molecular-cytogenetics-market

Globally, key players in the molecular cytogenetics industry are developing new instruments and tests for the molecular diagnosing, genetic screening and other tests. For instance, in July 2017, Quest Diagnostics announced the launch of a genetic screening service, QHerit. The service is for the detection of genetic risk associated to offspring through passing of heritable disorders. The QHerit Pan-Ethnic Expanded Carrier Screen is a panel of tests for the 22 heritable diseases cited under new screening guidelines issued in March 2017 by the American College of Gynecology (ACOG).

Some of the other key players operating in the molecular cytogenetics industry include Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories Inc., F. Hoffmann La-Roche AG, PerkinElmer Inc., Illumina Inc, Agilent Technologies Inc and NeoGenomics Inc.

Source: P&S Intelligence

Topical Drug Delivery Market to Witness the Highest Growth Globally in Upcoming Years

Drugs that are applied to a local area on the body are known as topical drugs. Many creams and balms that are used for skin treatment are frequently called topical drug. Topical drug delivery market offers an alternative drug delivery system to treat many diseases and related conditions such as psoriasis, ringworm, rashes & blisters and others. The topical drug delivery has turned out to be progressively essential in the pharmaceutical industry. Eye drops for ophthalmic use and various drugs utilized for inward breath in respiratory conditions such as asthma are also frequently known as topical medications. Topical medications have a local effect that means the effect of the drug will be only in the area where the drug has been applied; however, some topical medications can also have a systemic effect.

Browse report sample at: https://www.psmarketresearch.com/market-analysis/topical-drug-delivery-market/report-sample

The global topical drug delivery market is segmented on the basis of the product type, route of administration, indication for which the drug is used and its end users. Based on product type the market is segmented into formulations and devices, formulations are further sub-segmented into solid, liquid and semi-solid formulations, and devices. Semi-solid formulations include ointment, cream, gel lotion and paste and had a major contribution in the global topical drug delivery market in 2016, as compared to other sub-segments. The major factors driving the growth of semi-solid formulations include increasing rate of blood donations and rise in the number of surgical procedures such as organ transplantation where these formulations are widely used.

There are various factors that drive the growth of the topical drug delivery market including the increasing prevalence of dermal diseases, development of high technology in topical drug delivery systems, high number of cases of burn injuries, and increasing prevalence of diabetes, globally. According to the World Health Organization (WHO), the prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014, globally. Also, the WHO estimates that, diabetes would be the seventh leading cause of death, by 2030.

Browse report at: https://www.psmarketresearch.com/market-analysis/topical-drug-delivery-market

The high emergence and prevalence of novel diseases has led to the development of new medicines, and different companies are collaborating to strengthen their position in the market.

In January 2017, the United States Food and Drug Administration approved Rhofade (oxymetazoline hydrochloride) manufactured by Allergan plc for the topical treatment of persistent facial erythema associated with rosacea in adults. Rhofade is cream based formulation intended for topical administration.

Some of the other key players operating in the global topical drug delivery market include Crescita Therapeutics Inc., SOLVAY S.A., Bayer AG, Cipla Limited, Galderma S.A, GlaxoSmithKline PLC, Janssen Global Services, LLC. (Johnson and Johnson), Novartis International AG, Sienna Biopharmaceuticals, Inc., Allergan PLC.

Source: P&S Intelligence

At-Home DOA Testing Market - New Business Opportunities & Investment Research Report 2023

Global at-home DOA testing market is projected to attain a size of $831.9 million by 2023. The market is mainly driven by the increased production and trade of illicit drugs worldwide, growing use of illicit drugs amongst teenagers, and initiatives by government organizations to reduce the level of drug abuse.

Download free report sample at@  https://www.psmarketresearch.com/market-analysis/at-home-doa-testing-market/report-sample

On the basis of various types of products, the at-home DOA testing market has been categorized into rapid DOA test kits and breath analyzers. The market for rapid DOA test kits is expected to witness faster growth during the forecast period, attributed to the increasing adoption of various types of rapid DOA test kits, including test cups and dip cards. Also, these test kits are much cheaper as compared to breath analyzers.

Further, the rapid DOA test kits are bifurcated into test cups, test strips, test dip cards, and other types of kits. Amongst all these, the DOA test cups dominated the global rapid DOA test kits market in 2017. Extensive use of test cups for at-home urine drug testing is a key factor driving the market for this product category.

Browse full report at@  https://www.psmarketresearch.com/market-analysis/at-home-doa-testing-market ​​​​​​​

The companies operating in the at-home DOA testing industry are acquiring other firms and establishing their presence in different economies to increase their market share. Abbott Laboratories (Abbott) being a major player in the production of at-home DOA testing products acquired Alere Inc. in 2017, to increase its share in the point-of-care testing diagnostics market. The addition of this business aligns with Abbott's strategy for the growth of company and complements the leadership positions across its other businesses, which include medical devices, nutritional supplements, and pharmaceuticals.

Some of the other key players in the at-home DOA testing industry are UCP Biosciences Inc., Orient New Life Medical Co. Ltd., Express Diagnostics Int’l Inc., Assure Tech (Hangzhou) Co. Ltd., Psychemedics Corporation, Confirm BioSciences, Phamatech Inc., Home Health (U.K.) Ltd., and Quest Products Inc.

Source: P&S Intelligence